▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
In fiscal 2025, Q32 Bio Inc. recorded $53.74M of revenue, net income of $29.82M, and an operating cash outflow of $33.54M. The $53.74M revenue base provides substantial context for the company’s earnings, cash generation, and capital requirements. The company reported diluted EPS of $2.42, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 12.31M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 9.66M diluted shares in fiscal 2024, the current 12.31M base was 27.5% higher. Total assets stood at $61.78M, showing the scale of resources supporting revenue, earnings, liquidity, and financing. Asset turnover was 0.87x, relating the company’s annual revenue directly to the total assets reported at the period end.Profitability
The reported operating result was $16.90M, capturing profitability after direct costs and the operating expenses reflected in the statements. Relative to revenue, operating income represented 31.5%, showing how efficiently sales converted into operating profit. After all reported below-operating-line items, the company recorded net income of $29.82M for the fiscal year. Measured against reported revenue, net income produced a 55.5% margin after operating costs and the remaining recognized items. Reported EBITDA totaled $17.29M, adding a pre-interest, tax, depreciation, and amortization perspective to the profitability profile. The company recognized $0.00 of income tax for the period, completing the transition from pretax income to net income. Return on period-end equity was 71.0%, relating annual net income to the equity capital on the balance sheet. Return on period-end assets was 48.3%, connecting net income with the company’s total asset base. Net income of $29.82M replaced the $47.73M loss reported in fiscal 2024.Liquidity and Capital Structure
The company held $61.78M of assets against $19.76M of liabilities and $42.01M of equity, revealing how the asset base was financed. At period end, current assets of $55.05M compared with current liabilities of $11.35M, defining the company’s short-term resource position. At 4.85x, the current ratio shows that short-term assets were greater than short-term liabilities at period end. Reported cash and equivalents were $48.30M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 425.7% of current liabilities, showing how much near-term coverage came from cash alone. The equity-to-assets relationship was 68.0%, placing book capital against the total resource base. Liabilities represented 32.0% of total assets, quantifying the liability-funded share of the company’s resource base. Cash and equivalents equaled 78.2% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 33.1% from $92.33M in fiscal 2024, leaving current total assets lower year over year. Book equity was 640.3% higher than fiscal 2024 equity of $5.67M, showing how shareholder capital changed year over year. The reported cash balance changed 38.1% from $77.97M in fiscal 2024, ending lower year over year.Cash Flow and Earnings Quality
The company reported an operating cash outflow of $33.54M, rather than cash generation from operations. Operating cash flow and capital spending combined to leave a $33.54M cash deficit after capital spending. Relative to revenue, the post-investment cash deficit represented 62.4%. The cash deficit after capital spending represented 54.3% of the period-end asset base. Cash absorbed by operations decreased from $67.72M in fiscal 2024 to $33.54M.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .
Fundamentals Hub